Table 1 Susceptibility profiles of 89 clinical isolates belonging to the P. putida group. Strains were isolated from throat swabs (n = 26), rectal swabs (n = 46) and stool (n = 17) active screening cultures from 85 patients over period of 28 months
Antimicrobial agent | bla vim negative (n = 48) n(%) | bla vim positive (n = 41) n(%) | Totla (n = 89) n (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | R | I | S | R | I | S | R | I | S |
PIP | 20 (41.7) | – | 28 (58.3) | 41 (100) | – |  | 61 (68.5) | – | 28 (31.5) |
TZP | 18 (37.5) | – | 30 (62.5) | 41 (100) | – |  | 59 (66.3) | – | 30 (33.7) |
CAZ | 10 (20.8) | – | 38 (79.2) | 41 (100) | – |  | 51 (57.3) | – | 38 (42.7) |
FEP | 1 (2.1) | – | 47 (97.9) | 38 (92.2) | – | 3 (7.8) | 39 (43.8) | – | 50 (56.2) |
MEM | 16 (33.3) | 5 (10.4) | 27 (56.3) | 41 (100) | Â | Â | 57 (64.1) | 5 (5.6) | 27 (30.3) |
CIP | 2 (4.2) | 3 (6.3) | 43 (89.5) | 40 (97.6) | 1 (2.4) | Â | 42 (47.2) | 4 (4.5) | 43 (48.3) |
GEN | 0 (0) | – | 48 (100) | 13 (31.7) | – | 28 (68.3) | 13 (14.6) | – | 76 (85.4) |